PDCD1 and skin squamous cell carcinoma: Recently, the immune checkpoint inhibitor and the programmed cell death protein-1 (PD-1) blocking monoclonal antibody cemiplimab has been approved by FDA for treating patients with metastatic or locally advanced cSCC, who are not candidates for curative surgery or curative radiation therapy [42].